Sort by:
Results Per Page:
(+)-JQ1 based Degrader (PROTAC®) that selectively degrades BRD4
(+)-JQ1 based PROTAC® with selectivity for BRD4
Potent and selective BET bromodomain inhibitor; cell permeable
Negative Control for MZ 1 (Cat. No. 6154)
Potent and selective BRD9 Degrader (PROTAC®)
BET bromodomain inhibitor; also promotes differentiation of hiPSCs into megakaryocytes
Potent and selective BRD4(1) inhibitor
Potent and selective BRD9 inhibitor
RNA binding protein Lin28 inhibitor; promotes mESC differentiation; also bromodomain inhibitor
(+)-JQ1 based Degrader (PROTAC®) targeting BET bromodomains, active in vivo
Potent and selective BRD4 Degrader (PROTAC®)
Negative control of LY 294002 (Cat. No. 1130)
ERK5/BMK1 inhibitor; also BRD4 inhibitor
BET bromodomain inhibitor
CBP inhibitor; cell permeable
Broad spectrum bromodomain inhibitor
Potent CBP/p300 BRD inhibitor
Selective CBP/p300 BRD inhibitor
Selective BRD4(1) inhibitor
Potent and selective SMARCA2/4 and polybromo 1 inhibitor
Selective BRPF1B and BRPF2 inhibitor
BET bromodomain inhibitor; arrests cell cycle at G1 phase
Potent and selective BRPF1 inhibitor
Potent and selective BRPF bromodomain inhibitor
Potent and selective BRPF1B bromodomain inhibitor
Potent and selective BRD9 and BRD7 inhibitor; orally active
Negative control for (+)-JQ1
Selective BAZ2A and BAZ2B inhibitor
Dual BRD4 and CBP/p300 bromodomain inhibitor
Negative control for PF-CBP1
Selective BRD7 and BRD9 inhibitor
Negative Control for LP 99
Potent and selective CECR2 inhibitor
High affinity BRPF inhibitor
Potent and selective BRD1 and TAF1 inhibitor
Negative control for TP 472
High affinity BET bromodomain ligand
BET bromodomain inhibitor; orally bioavailable
Potent and selective BRPF1 inhibitor
Negative control for GSK 6853
High affinity and selective PCAF bromodomain inhibitor
Potent and high affinity BET bromodomain inhibitor; anti-inflammatory; orally bioavailable.
CECR2 and BPTF/FALZ inhibitor
Potent and selective BRD7/9 Degrader (PROTAC®)
Negative control for VZ 185 (Cat. No. 6936)
Potent BRD9 Degrader (PROTAC®)
Potent and selective (+)-JQ1 based Degrader (PROTAC®) targeting BET bromodomains, active in vivo
Potent BET bromodomain PROTAC®; also degrades BRD-tagged chimeric antigen receptors (CAR) in T cells